Track market-moving stories before they get noisy

Key Takeaways BD's Revello stent met the AGILITY trial's nine-month primary endpoint, with a failure rate of just 2.8%.Trial showed 97.2% primary patency and 98.3% freedom from clinically driven target lesion revascularization.BD's Revello stent remains investigational in the U.S., with clinical follow-up continuing through 36 months. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently reported positive nine-month results from the iliac cohort of the AGILITY trial evaluating its Revello Vascular Covered Stent for treating iliac artery disease, a form of peripheral artery disease (PAD). The findings, presented at VIVA 2026, showed promising safety and effectiveness and support continued clinical evaluation of the device.

The results are encouraging for BD as it seeks to strengthen its position in the peripheral vascular market through product innovation and clinical evidence. If subsequent follow-up confirms the device’s durability and effectiveness, Revello could expand BD’s growth opportunities in vascular intervention. Although Revello is CE-marked, it remains under clinical development in the United States and is limited to investigational use under U.S. law. Its commercial potential will depend on further clinical results and regulatory progress.

BDX Stock Trend Following the NewsFollowing the announcement on Oct. 7, BDX stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 2.7% against the industry’s 9.5% growth and the S&P 500’s 12.5% rise.

The positive AGILITY trial results could support BDX’s long-term growth by strengthening its portfolio of peripheral vascular intervention products and expanding clinical evidence for the Revello Vascular Covered Stent. Favorable outcomes may improve physician confidence in the device and support its adoption if it secures the necessary regulatory approvals.

This could create an additional growth opportunity for BD in treating peripheral artery disease while complementing its broader vascular portfolio. However, long-term revenue contribution will depend on the completion of clinical follow-up, regulatory clearance in the United States and the device’s eventual commercial uptake.

BDX currently has a market capitalization of $51.63 billion.

Image Source: Zacks Investment Research

AGILITY Trial Demonstrates Strong Safety and EffectivenessBD’s AGILITY Investigational Device Exemption trial evaluated the Revello Vascular Covered Stent in patients with iliac artery disease, which can restrict blood flow to the legs and feet, causing pain, cramping and reduced mobility. The iliac cohort enrolled 120 patients across 28 investigational sites in the United States, Europe, Australia and New Zealand. At nine months, the study met its primary composite safety and effectiveness endpoint, with a failure rate of just 2.8%, well below the prespecified performance goal of 19%.

The results also showed 97.2% primary patency, indicating that the treated arteries remained open. Trial data also demonstrated 98.3% freedom from clinically driven target lesion revascularization, suggesting a low need for repeat procedures due to clinical symptoms. Additionally, there were no device- or procedure-related deaths, no major amputations in the target limb at or above the ankle, or unanticipated serious adverse device effects. These findings support the stent’s performance in treating iliac artery disease, including cases involving moderate-to-severe lesion calcification.

Revello Stent Advances BD’s Peripheral Vascular PortfolioThe Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with radial resistive force tailored to the iliac arteries. Beyond safety and vessel patency, patients treated in the AGILITY trial showed improvements in disease severity and walking ability. The mean Rutherford category, a measure of peripheral artery disease severity, improved from 3.0 at baseline to 0.3 at nine months, while the mean Walking Impairment Questionnaire score increased by 31.7 points.

Women accounted for approximately 41% of enrolled patients, adding to the diversity of the study population. Clinical follow-up in the iliac cohort will continue through 36 months to assess the durability of the results. BD also completed enrollment in the trial’s superficial femoral and proximal popliteal artery cohort in August 2026, extending the study’s evaluation of the device across additional peripheral vascular applications.

Continued positive results and progress toward regulatory approval could strengthen BD’s competitive position in peripheral intervention, although broader commercial adoption will depend on longer-term clinical outcomes and regulatory developments.

Industry Prospects Favoring the MarketGoing by data provided by Grand View Research, the global iliac stent market size was valued at $1.2 billion in 2025 and is projected to grow from $1.3 billion in 2026 to $2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033.

Growth of the market can be attributed to growing advancements in medical technology, increasing prevalence of peripheral artery diseases and expanding awareness about minimally invasive procedures as an effective treatment option.

Other NewsBD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

Becton, Dickinson and Company (NYSE:BDX), a global medical technology firm and the largest domestic producer of critical medical consumables, on Tuesday announced a monumental partnership with the U.S. government.

The agreement aims to drastically expand domestic manufacturing and fortify the supply chain for vital medical products that patients and clinicians rely on daily.

Massive Investment in Domestic ProductionThe strategic alliance directly supports the Trump administration’s ongoing initiatives to scale up stateside manufacturing capacity and guarantee a robust supply chain for essential healthcare items.

To achieve this, the company plans to invest a staggering $19 billion across the U.S. over several years, encompassing capital, operational, and supply chain enhancements.

Read Next

Out of this massive total, the company will channel $3 billion exclusively into expanding key manufacturing facilities nationwide.

This expansion will boost end-to-end U.S. production by roughly 5 billion essential medical consumables every year.

As a result, the medical technology leader will elevate its share of domestically sourced consumables to approximately 80%.

American Steel and Tariff ReliefHighlighting its commitment to local sourcing, the manufacturer pledges to produce 100% of the needles it sells in America using solely American-made steel.

Furthermore, the landmark agreement shields the company from future Section 232 tariffs on specified products and materials, provided it meets agreed-upon operational milestones.

This exemption offers substantial long-term predictability for supply chain management. Because officials have yet to determine the final product scope and tariff rates, the company has not quantified the financial impact, but will provide updates when authorities finalize the actions.

BDX Price Action: Becton Dickinson shares were up 2.06% at $184.38 at the time of publication on Tuesday, according to Benzinga Pro data.

Read Next

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacy operations.

BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview Fairview operates one of the nation's largest health system pharmacy networks, filling an average of 20,000 prescriptions per week and providing medication access for patients across Minnesota through a network of 25 outpatient pharmacies and mail-order services. To keep pace with growing demand, the health system is making significant investments in centralized pharmacy operations that expand medication access, increase fulfillment capacity and improve the experience for patients who rely on increasingly complex therapies.

Many of the medications driving pharmacy growth today, including GLP-1s, biologics and other specialty therapies, are packaged, stored and fulfilled differently than traditional vial-based prescriptions. At the same time, retail pharmacy closures, a growing aging population, workforce shortages and the increasing prevalence of pharmacy deserts are creating new health care access challenges for patients.

To address these evolving demands, health systems are adopting centralized pharmacy operations and automation technologies that can support more complex medication fulfillment workflows. Widely used across Europe, BD Vmax introduces high-speed unit-of-use automation to the U.S. market, transforming how boxed medications are stored, tracked and fulfilled in central fill environments. Fairview's deployment of the BD Vmax 160 builds on its broader collaboration with BD and existing investment in pharmacy automation technologies, including the BD Parata™ Max 2 high speed vial filling robot.

"The future of pharmacy care will be shaped by health systems that can meet patients where they are, while creating more efficient and scalable models for medication access," said Matt Sassone, President, BD Pharmacy Automation. "Fairview's investment in centralized pharmacy services and intelligent automation reflects a bold vision for the future, demonstrating how health systems can transform pharmacy operations and expand access to therapies for the communities they serve."

Purpose-built for centralized fulfillment environments, the BD Vmax 160 is designed to automate labor-intensive workflows. The system helps pharmacies optimize inventory management, reduce manual dispensing activities and improve visibility into medication expiration dates, lot tracking and recall management processes, with features including:

Automated inventory replenishment, enabling overnight loading and inventory optimization with BD EasyLoad, which delivers a 3-second loading time per tote with 99.8% accuracy Automated labeling, eliminating time-consuming manual tasks while meeting labeling requirements for all 50 states Cold-chain capability, designed for 2–8°C environments to support proper medication storage and enhance medication safety Smart expiry detection that flags and tracks expiration dates upon loading and automatically blocks expired medications from dispensing, helping to reduce waste and support compliance As one of the largest providers of pharmacy automation and robotics solutions in healthcare, BD is advancing a vision for a more connected, intelligent end-to-end pharmacy. BD Vmax serves as an important step toward that future, complementing the company's broader portfolio of pharmacy automation technologies and the BD Incada™ Connected Care Platform. Together, these solutions help health systems automate and orchestrate pharmacy services from central pharmacy through dispensing and fulfillment, reducing manual touchpoints and moving toward more autonomous medication management. By connecting workflows across the medication-use process, BD is helping ensure patients receive the care they need across every stage of their care journey.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Key Takeaways BD enrolled 477 patients across 32 U.S. and European sites in the PREVENT trial.Phasix Mesh is being studied to prevent incisional hernias in high-risk abdominal surgery patients.Successful 24-month data could support BD's planned FDA submission for a new preventive indication. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently completed enrollment for its PREVENT clinical trial evaluating Phasix Mesh for preventing incisional hernias in high-risk patients undergoing elective open midline abdominal surgery.

For investors, the milestone reinforces BD's strategy of expanding its advanced tissue regeneration franchise through clinically backed innovation rather than relying solely on new product launches. Management has identified advanced tissue regeneration as one of its fastest-growing platforms, with double-digit growth and multiple clinical trials underway to broaden Phasix Mesh into new indications, making successful PREVENT data and a planned FDA submission a potential long-term growth catalyst.

Likely Trend of BDX Stock Following the NewsFollowing the announcement of the news, BDX shares have traded flat. In the year-to-date period, shares of the company have lost 2.6% against the industry’s 5.1% increase. However, the S&P 500 has risen 12.2% in the same timeframe.

The PREVENT enrollment milestone strengthens BD's long-term growth outlook by expanding Phasix Mesh beyond hernia repair into the largely untapped incisional hernia prevention market, where no products are currently approved in the United States. Successful 24-month data could support an FDA submission, open a new commercial opportunity while reinforcing the company's evidence-driven innovation strategy. The development also aligns with management's broader focus on advanced tissue regeneration, which has been delivering double-digit growth and remains a key long-term growth platform supported by multiple clinical expansion programs.

BDX currently has a market capitalization of $51.69 billion.

Image Source: Zacks Investment Research

More on the NewsThe PREVENT trial represents a key milestone in BD's effort to expand the use of its Phasix Mesh beyond traditional hernia repair into incisional hernia prevention, an area with a significant unmet medical need following abdominal surgery. The study enrolled 477 patients across 32 clinical sites in the United States and Europe, making it the first large-scale randomized trial to evaluate prophylactic reinforcement with a resorbable mesh for this indication, where no products currently have regulatory approval.

According to Rian Seger, worldwide president of Surgery at BD, the trial builds on the company's long-standing expertise in abdominal wall surgery while generating clinical evidence that could broaden the use of regenerative technologies for patients at risk of post-surgical complications.

The trial is designed to evaluate Phasix Mesh in high-risk patients undergoing elective open midline abdominal surgery, with the goal of establishing robust clinical evidence for preventing incisional hernias. Patients will be followed through the study's primary endpoint at 24 months, while longer-term follow-up extending to five years will further assess safety and clinical outcomes.

Upon completion of the primary endpoint assessments, BD expects the findings to support a planned submission to the FDA, potentially paving the way for a label expansion into a new preventive surgical indication. The milestone also aligns with management's broader strategy, outlined during its fiscal third-quarter earnings call, of using multiple clinical programs to expand the advanced tissue regeneration platform into new indications as a long-term growth driver.

Advanced Tissue Regeneration Pipeline Extends Beyond PREVENTBeyond the PREVENT study, BD is advancing multiple clinical trials aimed at expanding its advanced tissue regeneration portfolio into new applications. Management said that the Phasix biomaterial platform remains one of the company's key long-term growth drivers, with several ongoing studies evaluating its use across additional indications beyond abdominal wall surgery. The company expects these evidence-generation efforts, alongside continued double-digit growth in the business, to strengthen its presence in regenerative surgery and support future commercial expansion.

Other NewsRecently, BD exited the third quarter of fiscal 2026 with better-than-expected results and solid top- and bottom-line results. Robust performances by all segments and both geographic regions were encouraging.

Apart from these, there were a few other developments during the recent period. BDX was awarded a Vizient Innovative Technology contract for the BD CentroVena One Insertion System.

The company launched the Elyra Thulium Fiber Laser System, thus expanding its kidney stone care portfolio. BD also announced a collaboration with Brazil-based pharmaceutical company EMS to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report)  West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.

"We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value."

Recent Business Highlights

Medical Essentials: Awarded a Vizient Innovative Technology contract for the BD® CentroVena One™ Insertion System, validating CentroVena One™ Insertion System as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety. BioPharma Systems: Announced a collaboration with EMS, one of Brazil's leading pharmaceutical companies, to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes. Interventional:  Launched the Elyra™ Thulium Fiber Laser System, expanding BD's kidney stone care portfolio with a system designed to help urology teams enhance efficiency, versatility and procedural workflow. BD named to TIME's 2026 List of America's Best Companies. BD issued its Fiscal Year 2025 Together We Advance Corporate Sustainability Report. Basis of Presentation— Continuing Operations

On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.

Third Quarter Fiscal 2026 Operating Results

(Millions of dollars, except per share amounts)

Three Months Ended June 30,

Reported
Change 

Foreign Currency
Neutral Change1

2026

2025

Revenues

$                4,983

$                4,726

5.4 %

4.4 %

Reported Diluted Earnings per Share

$                  1.64

$                  1.57

4.5 %

3.8 %

Adjusted Diluted Earnings per Share1

$                  3.23

$                  3.08

4.9 %

3.9 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Geographic Results

Revenues (Millions of dollars)

Three Months Ended June 30,

Reported
Change

Foreign Currency
Neutral Change1

2026

2025

United States

$                3,081

$                2,882

6.9 %

6.9 %

International

$                1,902

$                1,844

3.2 %

0.6 %

Total Revenues

$                4,983

$                4,726

5.4 %

4.4 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Segment Results

Revenues (Millions of dollars)

Three Months Ended June 30,

Reported
Change

Foreign Currency
Neutral Change1

2026

2025

Medical Essentials2

$                 1,675

$                 1,602

4.5 %

3.2 %

Connected Care2

$                 1,224

$                 1,166

4.9 %

4.4 %

BioPharma Systems2

$                    670

$                    629

6.6 %

5.2 %

Interventional2

$                 1,414

$                 1,328

6.4 %

5.5 %

Total Revenues

$                 4,983

$                 4,726

5.4 %

4.4 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. 

2Effective October 1, 2025, the company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

Full Year Fiscal 2026 Guidance

The company updates its full year fiscal 2026 guidance as follows; expects revenue growth toward the high end of its range and raises the midpoint of adjusted diluted EPS guidance.

Updated New BD Guidance

as of August 6, 2026

Prior New BD Guidance

as of May 7, 2026

GAAP Revenue Growth

Low single-digit plus

Low single-digit plus

Revenue Growth (FXN)

Low single-digit

Low single-digit

Adjusted Diluted EPS

$12.62 to $12.72

$12.52 to $12.72

BD's guidance for full year fiscal 2026 reflects numerous assumptions that could affect its business, based on the information management has reviewed as of this date. Management will discuss its guidance and several of its assumptions on its third fiscal quarter earnings call. 

The company's expected adjusted diluted EPS for fiscal 2026 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our revenue growth for our 2026 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying revenue performance for our 2026 fiscal year in relation to our underlying 2025 fiscal year performance.

Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts and news media to discuss its third quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors, at 8 a.m. (ET) Thursday, August 6, 2026. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-688-9445 (domestic) and 402-220-1371 (international) through the close of business on Thursday, August 13, 2026. A confirmation number is not needed to access the replay.

Non-GAAP Financial Measures/Financial Tables
This press release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral basis, adjusted diluted earnings per share and free cash flow. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. 

We present adjusted diluted earnings per share for the third quarter and the first nine months of fiscal year 2026, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, separation-related costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, certain pension settlement costs, and the impact of the extinguishment of debt. 

We also present revenue growth rates for the third quarter and the first nine months of fiscal year 2026 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior period. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods. 

We also present free cash flow for the first nine months of fiscal year 2026 over the corresponding prior period, which is net cash provided by continuing operating activities less capital expenditures, to provide a view of the Company's ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary expenditures given that we have certain non-discretionary obligations such as debt service that are not deducted from the measure. We believe the presentation of results of free cash flow in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior period.

New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD. 

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

***

This press release and accompanying audio webcast on August 6, 2026 contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, statements relating to future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including volatility resulting from the imposition of (and changing policies around) tariffs enacted by the U.S. government (and related countermeasures by non-U.S. governments), or our ability to mitigate the impact of such tariffs, including developments regarding refunds of certain tariffs and/or the collection of remaining refunds of certain tariffs; import or export licensing requirements and other governmental restrictions; reductions in U.S. government funding for healthcare, disruptions in global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products; inflationary pressures, currency and interest rate fluctuations, global oil prices and increased borrowing costs; conditions in international markets, including geopolitical developments such as the continuation and/or escalation of evolving situations in Iran and the Middle East region (which could result in continued disruption of transportation lanes and global energy supplies, as well as increases in global oil prices and adversely affect our supply chain costs, ability to source raw materials and components and our ability to deliver product to customers), Ukraine and Asia; competitive factors, including changing customer and patient preferences and requirements, such as decreased demand for our products as a result of changes to U.S. federal and state policies (such as for pharmaceutical products and vaccines), and increased demand for products utilizing evolving technologies (including emerging technologies utilizing artificial intelligence ("AI")), as well as new products or novel medical therapies introduced by competitors; changes in research and development efforts, investment or suspension by pharmaceuticals companies with regard to vaccine development; changes in reimbursement practices and coverage policies and third-party payer cost containment measures and health insurance coverage levels and costs; decreases or delays in purchases of our products due to reduced research and development spending; product efficacy or safety concerns and related regulatory actions, changes to the labeled indications or permitted uses of our products, non-compliance with applicable regulatory requirements regarding our products, including marketing authorization, registration, quality system and manufacturing requirements (including as a result of product modifications), or other factors that could result in product recalls, field actions, lost revenue, restrictions on our ability to continue selling existing products or commercialize new products (including limitations on future product clearances or approvals and the imposition of civil penalties); increased exposure to product liability or other claims and damage to our reputation (including products we acquire through acquisitions); changes to legislation or regulations that may impact U.S. or foreign healthcare systems, changes in medical or clinical practices or in customer and patient preferences, efforts to improve compliance of healthcare practitioners, potential cuts or freezes in healthcare spending and/or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; policy and regulatory changes that may be implemented by the U.S. government, including the further elimination, downsizing and/or reduced funding of certain government agencies and programs, as well as further changes in the policy positions of such agencies (including those related to pharmaceutical products and vaccines); other new or changing laws and regulations impacting our business, including changes in tax laws, new and changing environmental laws and regulations (such as those related to sustainability, climate change or materials of concern) and new and changing cybersecurity, AI or privacy laws; other changes in laws impacting international trade or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; any adverse impact related to the development, deployment and use of AI in our products and business operations; labor disruptions; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in raw material, component, labor, duties, freight, energy and other production costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of natural disasters and public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to achieve or maintain growth of our portfolio; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission (the "SEC")); the issuance of new or revised accounting standards; our ability to execute our New BD strategy, Excellence Unleashed, as expected; and other factors discussed in BD's filings with the SEC. Tariff commentary is based on tariff policies in effect as of August 5, 2026. International trade policies, trade restrictions and tariffs (and related countermeasures and developments regarding refunds of certain tariffs) are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contacts:
Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
Media: Matt Marcus, VP, Public Relations - [email protected] 

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Three Months Ended June 30,

2026

2025

% Change

Revenues

$

4,983

$

4,726

5.4

Cost of products sold

2,668

2,491

7.1

Selling and administrative expense

1,261

1,163

8.4

Research and development expense

258

230

12.0

Integration, restructuring and transaction expense

89

96

(6.9)

Other operating expense, net

44

7

544.7

Total Operating Costs and Expenses

4,320

3,986

8.4

Operating Income

663

739

(10.3)

Interest expense

(132)

(152)

(13.4)

Interest income

4

4

(15.8)

Other income (expense), net

19

(22)

183.9

Income from Continuing Operations Before Income Taxes

554

569

(2.7)

Income tax provision

102

118

(13.2)

Net Income from Continuing Operations

451

451

0.1

(Loss) Income from Discontinued Operations, Net of Tax

(74)

123

(159.8)

Net Income

$

377

$

574

(34.3)

Basic Earnings Per Share

Income from Continuing Operations

$

1.64

$

1.57

4.5

(Loss) Income from Discontinued Operations

(0.27)

0.43

(162.8)

Basic Earnings per Share

$

1.37

$

2.00

(31.5)

Diluted Earnings Per Share

Income from Continuing Operations

$

1.64

$

1.57

4.5

(Loss) Income from Discontinued Operations

(0.27)

0.43

(162.8)

Diluted Earnings per Share

$

1.37

$

2.00

(31.5)

Average Shares Outstanding (in thousands)

Basic

274,788

287,170

Diluted

275,158

287,223

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Nine Months Ended June 30,

2026

2025

% Change

Revenues

$

14,183

$

13,539

4.8

Cost of products sold

7,662

7,646

0.2

Selling and administrative expense

3,703

3,435

7.8

Research and development expense

742

706

5.1

Integration, restructuring and transaction expense

729

277

162.9

Other operating expense, net

122

70

74.9

Total Operating Costs and Expenses

12,958

12,134

6.8

Operating Income

1,225

1,405

(12.8)

Interest expense

(434)

(458)

(5.1)

Interest income

16

31

(47.4)

Other income (expense), net

97

(72)

234.4

Income from Continuing Operations Before Income Taxes

904

906

(0.2)

Income tax provision

179

151

18.5

Net Income from Continuing Operations

725

755

(4.0)

(Loss) Income from Discontinued Operations, Net of Tax

(276)

430

(164.3)

Net Income

$

449

$

1,185

(62.1)

Basic Earnings Per Share

Income from Continuing Operations

$

2.59

$

2.62

(1.1)

(Loss) Income from Discontinued Operations

(0.99)

1.49

(166.4)

Basic Earnings per Share

$

1.60

$

4.11

(61.1)

Diluted Earnings Per Share

Income from Continuing Operations

$

2.58

$

2.62

(1.5)

(Loss) Income from Discontinued Operations

(0.98)

1.49

(165.8)

Diluted Earnings per Share

$

1.59

$

4.10

(61.2)

Average Shares Outstanding (in thousands)

Basic

280,332

287,997

Diluted

281,603

288,693

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited; Amounts in millions)

June 30, 2026

September 30, 2025

Assets

Cash and equivalents

$

708

$

567

Restricted cash

155

210

Short-term investments

1

8

Trade receivables, net

2,364

2,396

Inventories

3,316

3,149

Prepaid expenses and other

1,595

1,379

Current assets of discontinued operations

—

1,545

Total Current Assets

8,139

9,255

Property, plant and equipment, net

6,083

6,383

Goodwill and other intangibles, net

33,964

35,190

Other assets

2,546

2,383

Noncurrent assets of discontinued operations

—

2,114

Total Assets

$

50,731

$

55,325

Liabilities and Shareholders' Equity

Current debt obligations

$

3,297

$

1,559

Other current liabilities

6,107

6,106

Current liabilities of discontinued operations

—

648

Long-term debt

13,511

17,620

Long-term employee benefit obligations

1,005

1,027

Deferred income taxes and other liabilities

2,394

2,632

Noncurrent liabilities of discontinued operations

—

342

Shareholders' equity

24,416

25,390

Total Liabilities and Shareholders' Equity

$

50,731

$

55,325

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; Amounts in millions)

Nine Months Ended June 30,

2026

2025

Operating Activities

Net income

$

449

$

1,185

Less: (Loss) income from discontinued operations, net of tax

(276)

430

Income from continuing operations, net of tax

725

755

Depreciation and amortization

1,697

1,706

Change in operating assets and liabilities and other, net

(319)

(883)

    Net Cash Provided by Continuing Operating Activities

2,104

1,578

Investing Activities

Capital expenditures

(376)

(383)

Maturities and sales of investments

27

408

Acquisitions, net of cash acquired and adjustments

(22)

13

Other, net

(192)

(267)

    Net Cash Used for Continuing Investing Activities

(563)

(229)

Financing Activities

Change in short-term debt

37

133

Proceeds from long-term debt

704

—

Distribution from spin-off entity, net

3,857

—

Payments of debt

(2,696)

(1,208)

Repurchases of common stock

(2,250)

(750)

Dividends paid

(875)

(899)

Other, net

(70)

(83)

    Net Cash Used for Continuing Financing Activities

(1,293)

(2,807)

Discontinued Operations

Net cash (used for) provided by operating activities

(198)

498

Net cash used for investing activities

(40)

(96)

Net cash provided by (used for) financing activities

71

(8)

    Net Cash (Used for) Provided by Discontinued Operations

(167)

395

Effect of exchange rate changes on cash and equivalents and restricted cash

5

(2)

    Net increase (decrease) in cash and equivalents and restricted cash

86

(1,065)

Opening Cash and Equivalents and Restricted Cash

777

1,792

Closing Cash and Equivalents and Restricted Cash

$

863

$

727

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended June 30,

(Unaudited; Amounts in millions)

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

720

$

680

5.9

$

444

$

452

$

13

(1.8)

(4.7)

$

1,164

$

1,132

$

13

2.8

1.6

Specimen Management

274

240

14.0

237

230

8

3.1

(0.2)

511

470

8

8.7

7.0

Total

$

994

$

920

8.0

$

681

$

682

$

21

(0.1)

(3.2)

$

1,675

$

1,602

$

21

4.5

3.2

Connected Care(1)

Medication Management Solutions

$

737

$

709

3.9

$

178

$

179

$

6

(0.4)

(4.0)

$

915

$

888

$

6

3.0

2.3

Advanced Patient Monitoring

189

176

7.4

120

102

(1)

17.1

17.8

309

278

(1)

10.9

11.2

Total

$

926

$

885

4.6

$

297

$

281

$

6

5.9

3.9

$

1,224

$

1,166

$

6

4.9

4.4

BioPharma Systems(1)(2)

$

204

$

178

14.2

$

467

$

451

$

9

3.6

1.6

$

670

$

629

$

9

6.6

5.2

Interventional(1)

Peripheral Intervention

$

294

$

271

8.4

$

258

$

241

$

9

7.2

3.5

$

552

$

512

$

9

7.8

6.1

Urology and Critical Care

357

334

7.1

82

88

—

(6.7)

(6.9)

440

422

—

4.2

4.2

Surgery

306

294

4.3

116

101

3

15.0

11.7

422

395

3

7.0

6.2

Total

$

957

$

898

6.6

$

457

$

430

$

12

6.2

3.3

$

1,414

$

1,328

$

12

6.4

5.5

Total Revenues from Continuing Operations

$

3,081

$

2,882

6.9

$

1,902

$

1,844

$

48

3.2

0.6

$

4,983

$

4,726

$

48

5.4

4.4

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Nine Months Ended June 30,

(Unaudited; Amounts in millions)  

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

2,124

$

2,060

3.1

$

1,331

$

1,313

$

56

1.4

(2.9)

$

3,455

$

3,373

$

56

2.4

0.8

Specimen Management

772

721

7.2

690

667

32

3.5

(1.2)

1,463

1,387

32

5.4

3.1

Total

$

2,897

$

2,781

4.2

$

2,021

$

1,979

$

88

2.1

(2.3)

$

4,918

$

4,760

$

88

3.3

1.5

Connected Care(1)

Medication Management Solutions

$

2,076

$

2,030

2.3

$

502

$

470

$

27

6.8

1.2

$

2,578

$

2,500

$

27

3.1

2.1

Advanced Patient Monitoring

547

490

11.7

350

317

5

10.6

9.1

897

806

5

11.3

10.7

Total

$

2,623

$

2,520

4.1

$

852

$

787

$

31

8.3

4.4

$

3,475

$

3,307

$

31

5.1

4.2

BioPharma Systems(1)(2)

$

532

$

431

23.4

$

1,157

$

1,191

$

41

(2.8)

(6.2)

$

1,689

$

1,622

$

41

4.1

1.6

Interventional(1)

Peripheral Intervention

$

839

$

793

5.8

$

713

$

673

$

29

6.0

1.6

$

1,552

$

1,466

$

29

5.9

3.9

Urology and Critical Care

1,047

962

8.8

250

249

5

0.4

(1.8)

1,297

1,211

5

7.1

6.6

Surgery

919

885

3.8

333

288

13

15.8

11.1

1,252

1,173

13

6.8

5.6

Total

$

2,805

$

2,640

6.2

$

1,296

$

1,209

$

48

7.2

3.2

$

4,101

$

3,849

$

48

6.5

5.3

Total Revenues from Continuing Operations

$

8,857

$

8,372

5.8

$

5,326

$

5,166

$

208

3.1

(0.9)

$

14,183

$

13,539

$

208

4.8

3.2

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

Three Months Ended June 30,

(Unaudited)

Three Months Ended June 30,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted Earnings per Share from Continuing Operations

$

1.64

$

1.57

$

0.07

$

0.01

$

0.06

4.5

%

3.8

%

Purchase accounting adjustments ($363 million and $376 million pre-tax, respectively) (1)

1.32

1.31

—

Integration costs ($41 million and $37 million pre-tax, respectively) (2)

0.15

0.13

—

Restructuring costs ($48 million and $57 million pre-tax, respectively) (2)

0.18

0.20

0.03

Transaction costs ($1 million pre-tax) (3)

—

0.01

—

Separation-related items ($32 million pre-tax) (4) 

0.12

—

—

Product, litigation, and other items ($53 million and $44 million pre-tax, respectively) (5)

0.19

0.15

—

Tax impact of specified items and other tax related (($101) million and $(82) million, respectively)

(0.37)

(0.29)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

3.23

$

3.08

$

0.15

$

0.03

$

0.12

4.9

%

3.9

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities.

(3)

Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the three months ended June 30, 2026 reflects charges to adjust the estimate of certain future product remediation costs, various legal matters, and pension settlement costs. The amount for the three months ended June 30, 2025 reflects a charge of $30 million recorded to Other income (expense), net, related to pension settlement costs.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

Nine Months Ended June 30,

(Unaudited)

Nine Months Ended June 30,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted Earnings per Share from Continuing Operations

$

2.58

$

2.62

$

(0.04)

$

0.05

$

(0.09)

(1.5)

%

(3.4)

%

Purchase accounting adjustments ($1.113 billion and $1.481 billion pre-tax, respectively) (1)

3.95

5.13

0.01

Integration costs ($123 million and $87 million pre-tax, respectively) (2)

0.44

0.30

—

Restructuring costs ($605 million and $185 million pre-tax, respectively) (2)

2.15

0.64

0.05

Transaction costs ($5 million pre-tax) (3)

—

0.02

—

Separation-related items ($73 million pre-tax) (4)

0.26

—

—

Product, litigation, and other items ($193 million and $255 million pre-tax, respectively) (5)

0.68

0.88

—

Impacts of debt extinguishment (($122) million pre-tax)

(0.43)

—

—

Tax impact of specified items and other tax related (($292) million and ($273) million, respectively)

(1.04)

(0.95)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

8.59

$

8.65

$

(0.06)

$

0.11

$

(0.17)

(0.7)

%

(2.0)

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities. Restructuring costs for the nine months ended June 30, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed. These exit actions are aimed at simplifying the Company's operations and aligning resources behind its most value-creating platforms. The impairment charges are primarily reflected as decreases of $238 million within Property, plant and equipment, net, and $134 million within Goodwill and other intangibles, net, on the Company's June 30, 2026 condensed consolidated balance sheet.

(3)

Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the nine months ended June 30, 2026 reflects charges of $57 million recorded to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $75 million recorded to Other operating expense, net, related to various legal matters, and a charge of $43 million recorded to Other income (expense), net, related to pension settlement costs. The amount for the nine months ended June 30, 2025 reflects charges of $98 million recorded to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $64 million recorded to Other operating expense, net, related to various legal matters, and a charge of $30 million recorded to Other income (expense), net, related to pension settlement costs.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW

Nine Months Ended June 30,

(Unaudited)

A

B

C=A-B

D=C/B

2026

2025

Change

% Change

Net Cash Provided by Continuing Operating Activities

$

2,104

$

1,578

$

526

33.3

%

Capital Expenditures

(376)

(383)

7

(1.7)

%

Free Cash Flow

$

1,728

$

1,195

$

532

44.6

%

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION

Full Year FY2025

Full Year FY2026 Guidance

($ in millions)

% Change

BDX Reported Revenues from Continuing Operations

$

18,544

FY2026 Reported Revenue Growth

Low single-digit plus

Illustrative Foreign Currency (FX) Impact

~+100 basis points

FY2026 Revenue Growth (FXN)

Low single-digit

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION CONTINUED

Full Year FY 2026 Guidance

Full Year FY2025

Total Company

Reported Diluted Earnings per Share from Continuing Operations

$

3.81

Purchase accounting adjustments ($1.865 billion pre-tax) (1)

6.46

Integration costs ($127 million pre-tax) (2)

0.44

Restructuring costs ($270 million pre-tax) (2)

0.93

Transaction costs ($6 million pre-tax) (3)

0.02

Separation-related items ($3 million pre-tax) (4)

0.01

Product, litigation, and other items ($506 million pre-tax) (5)

1.75

Tax impact of specified items and other tax related (($443) million)

(1.54)

Adjusted Diluted Earnings per Share from Continuing Operations

$

11.90

$12.62 to $12.72

Reported % Change

+6.1% to +6.9%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities.

(3)

Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects charges of $98 million to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $297 million to Other operating expense, net, related to product liability and certain other legal matters, and charges of $38 million to Other expense, net, related to pension settlement costs.

SOURCE BD (Becton, Dickinson and Company)

CompaniesJuly 31 (Reuters) - Becton Dickinson (BDX.N), opens new tab said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users ​reported difficulty in removing a part of the device after ‌using it on patients.

Here are some details:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The product, called an intraosseous needle set, is used to deliver fluids and medicine quickly into a patient's bone when ​a regular IV line cannot be used fast enough. This is ​often done in emergencies, such as cardiac arrest or severe ⁠trauma.

Becton said the issue involves a part called the obturator, or ​stylet, which sometimes cannot be removed after the needle is inserted.

The company ​said this incident can happen if the drill used to insert the needle is not pulled straight back, or if the obturator is rotated the wrong way ​when taken out.

As of June 2026, BD said it had received 75 ​complaints and 45 reports of serious injury related to the problem. The company also ‌said ⁠four patients died when the part could not be removed during resuscitation efforts for people who had suffered cardiac arrest outside a hospital.

The affected needle sets were made with parts slightly out of the normal ​size range and were ​shipped between ⁠September 30, 2024, and June 12, 2026.

The recall does not include the intraosseous powered driver, which is the ​tool used to insert the needles.

BD said that if ​the obturator ⁠cannot be removed, medical staff may need to get a new needle or switch to another way of giving treatment, like a peripheral IV ⁠catheter. That ​delay could be dangerous, especially for critically ​ill patients, the company said.

The U.S. Food and Drug Administration has been informed about the ​recall, BD said.

Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter.  The news release and related presentation materials will be made available at www.bd.com/investors.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Also from this source